Relief Therapeutics (OTCMKTS:RLFTF) stock is witnessing mild fall in the mid-day session on Wednesday on moderate volume.
As of 12:29, RLFTF stock moved down 0.70% to $0.2503 with more than 1.20 million shares, compared to its average volume of 6.68 million shares. The stock has moved within a range of $0.2426 – 0.2588 after opening the trade at $0.2426.
Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, has Announced Additional Results from the Aviptadil U.S. Expanded Access Protocol for Patients with Critical COVID-19
- RLFTF reported today that its collaboration partner, NRx Pharmaceuticals, Inc., (NRXP) (“NRx”) has announced additional results from the aviptadil U.S. Expanded Access Protocol (EAP).
- The EAP included 240 patients in the intensive care unit (ICU) with critical COVID-19 respiratory failure requiring either invasive or non-invasive mechanical ventilation, or high flow rate oxygen bynasal cannula, and not eligible for the recently completed phase 2b/3 clinical trial with IV aviptadil. According to NRx’s press release, these EAP data are being submitted by NRx to the U.S. Food and Drug Administration (FDA) as “real world” evidence in support of the findings from the phase 2b/3 trial. The related NRx press release can be accessed through the following link.
“We are a materials design company using leading-edge technologies to design customer and market-focused solutions. The long-term agreement with NanoXplore complements our approach, which is to customize solutions to maximize performance through collaborations and the leveraging of leading-edge technology.”